(Q72524724)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

title

A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference

1 reference

1 February 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Medicine

27 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

volume

98

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

page(s)

156-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial

27 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The clinical and health status of patients with recent-onset rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The course of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Management of early inflammatory arthritis. The long-term outcome and justification for early treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Should disease-modifying agents be used in mild rheumatoid arthritis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Therapeutic criteria in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Measuring health status in arthritis. The arthritis impact measurement scales.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Measurement of outcome in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The use of Amsler grids in early chloroquine retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Hydroxychloroquine is safe and probably useful in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The mortality of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Long-term outcome of treating rheumatoid arthritis: results after 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

The work dynamics of the person with rheumatoid arthritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Secular changes in published clinical trials of second-line agents in rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Arthritis education: opportunities and state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Coping with rheumatoid arthritis: is one problem the same as another?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

Arthritis self-management studies: a twelve-year review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980399-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)80399-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7847432%20AND%20SRC:MED&resulttype=core&format=json

27 October 2019

1 reference